P3 Health Partners Inc. PIII PHARMA
Company Overview
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.
Why Investors Should Care
Revenue has grown at a 46.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $1.46B (-2.8% YoY); net profit $-147.95M.
- Trailing 12 Months Year-on-year growth — revenue +8.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 46.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 46.85% |
| 1 Year: | 8.60% |
Stock Price Performance
| 1 Year: | +26.48% |
| 6 Months: | +211.27% |
| 3 Months: | -26.69% |
| 1 Month: | -22.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 46.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 45.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PIII P3 Health Partners Inc. PHARMA | 8.98 | -0.27 | $35.13M | 0.00% | - | - | 46.85% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 151.30M | 144.59M | 156.19M | 273.54M | 269.45M | 248.26M | 302.08M | 329.09M | 288.35M | 388.49M | 379.16M | 362.12M | - | 373.23M | 355.79M | 345.25M | 384.81M | 386.39M | 386.38M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 411.31M | 389.91M | 389.48M | 538.68M | 378.15M | - |
| Operating Income | -12.99M | -25.97M | -28.12M | -52.17M | -912.19M | -60.01M | -48.82M | -21.03M | -33.82M | -43.83M | -31.33M | -106.99M | - | -38.09M | -34.12M | -44.22M | -153.87M | 8.24M | 41.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.40M | -10.46M | -27.89M | -130.12M | 29.88M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.72M | 10.14M | 20.53M | 15.64M | 16.77M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.17M | -41.68M | -69.45M | -166.75M | -7.96M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07M | 1.98M | 11.00K | -1.04M | -11.00M | - |
| Net Income | -24.65M | -29.46M | -32.05M | -10.58M | -154.35M | -11.17M | -9.20M | -9.82M | -13.30M | -18.70M | -12.02M | -46.51M | - | -20.48M | -20.36M | -31.59M | -75.52M | 1.22M | 7.44M |
| Diluted EPS | - | - | - | -0.25 | -3.73 | -0.27 | -0.22 | -0.09 | -0.12 | -7.86 | -7.37 | -15.70 | - | -6.28 | -6.23 | -9.67 | -23.02 | 0.32 | -0.63 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 145.48M | 491.06M | 578.60M | 1.05B | 1.27B | 1.50B | 1.46B |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 1.30B | 1.43B | 1.81B | 1.73B |
| Operating Income | -39.54M | -28.59M | -129.06M | -245.96M | -167.93M | -312.60M | -270.30M |
| EBITDA | - | - | - | -1.46B | -81.07M | -197.76M | -181.86M |
| Interest Expense | - | - | - | 11.40M | 15.98M | 22.17M | 55.03M |
| Pretax Income | - | - | - | -1.56B | -183.73M | -305.99M | -321.06M |
| Tax Provision | - | - | - | 1.86M | 2.69M | 4.39M | 2.02M |
| Net Income | -41.97M | -31.41M | -146.40M | -270.13M | -57.77M | -135.85M | -147.95M |
| Diluted EPS | - | - | - | -325.00 | -31.50 | -54.00 | -45.26 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 106.44M | - | 876.57M | 860.97M | 783.42M | 656.64M |
| Current Assets | - | - | - | 100.69M | 166.02M | 184.14M | 133.08M |
| Cash & Equivalents | 32.59M | 36.26M | - | 17.54M | 36.32M | 38.82M | 25.01M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 72.09M | 118.50M | 121.27M | 92.46M |
| Total Liabilities | - | 145.96M | - | 353.91M | 427.31M | 633.89M | 796.88M |
| Current Liabilities | - | 90.62M | - | 241.66M | 299.37M | 496.42M | 545.26M |
| Long Term Debt | - | 45.39M | - | 94.42M | 108.32M | 108.91M | 228.37M |
| Total Debt | - | - | - | 105.94M | 121.94M | 195.40M | 284.88M |
| Total Equity | - | - | - | 5.85M | 142.13M | 75.94M | -155.23M |
| Shares Outstanding | - | - | - | 831.58K | 2.33M | 3.26M | 3.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -28.29M | -24.60M | -51.13M | -126.02M | -76.03M | -110.13M | -91.24M |
| Investing Cash Flow | -3.86M | -3.17M | -8.21M | -7.73M | -1.83M | 14.53M | 129.00K |
| Financing Cash Flow | 63.62M | 34.76M | 24.79M | 11.38M | 100.33M | 98.77M | 72.81M |
| Capital Expenditure | -1.45M | -2.93M | -3.29M | -2.23M | -1.83M | - | - |
| Free Cash Flow | -29.74M | -27.52M | -54.42M | -128.25M | -77.86M | -110.13M | -91.24M |
| Net Change in Cash | - | - | - | -122.38M | 22.48M | 3.17M | -18.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -27.2% | -5.8% | -22.3% | -23.4% | -13.3% | -20.8% | -18.5% |
| Net Margin % | -28.8% | -6.4% | -25.3% | -25.7% | -4.6% | -9.1% | -10.1% |
| ROE % | - | - | - | -4,614.4% | -40.6% | -178.9% | 95.3% |
| ROCE % | - | -180.7% | - | -38.7% | -29.9% | -108.9% | -242.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 1.40% | 54.72K | $419.68K |
| 2 | Jane Street Group, LLC | 1.39% | 54.49K | $417.98K |
| 3 | Vanguard Capital Management LLC | 1.06% | 41.48K | $318.18K |
| 4 | Trinity Financial Advisors LLC | 0.86% | 33.54K | $257.25K |
| 5 | MYDA Advisors LLC | 0.51% | 20.00K | $153.40K |
| 6 | Corient Private Wealth LP | 0.50% | 19.74K | $151.38K |
| 7 | Geode Capital Management, LLC | 0.44% | 17.10K | $131.13K |
| 8 | Scientech Research LLC | 0.42% | 16.32K | $125.16K |
| 9 | Abundance Wealth Counselors | 0.41% | 16.00K | $122.72K |
| 10 | Renaissance Technologies, LLC | 0.39% | 15.15K | $116.19K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PIII
Discipline and Rules-Based Execution in PIII Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQWDlaWDBua0xXMzFxV01aSDExY0s1OGdSc1RMcGZhSS0zczlKSjQ3eVk3RWs0MjFfakhoeEsyR2FYUmtpVlZFYnVxQmFKbXBoaGhkNmZBaEFEQ2prVng3djhPQk5KZmcyYlktMTZKN3BpbnlrakQwTW1WRHhBSjVtQ1U3RmJNQWpMbk51U3…
P3 Health Partners (PIII) Stock Sees Fair Value Lift After Strong EBITDA And Guidance - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxONl9YNXlDWkNIMEZfWlM4RFh6V1RTekdwM05uSTlORHRJa3dYYWxheXp6NE95eEEyUnlZZk9MeDlkZ0luMjlQRGt4N2ZSUzZ4a3VXdWdVUUVaRlRsdF9oMTFTYkV1SGcwczhMUnQ3RjRWR3NyOGt5ZTdicm9jT1lmM204WHN4MnRyMnpUOU…
PIII - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5MTTNVQWVhNzM1cEdIanU3bUc3ZEctQ3h4YWllYjAtNVB2c21DLTVudjVYYnhIeDJUdXVRa1J6Q0xraU5FWVE?oc=5" target="_blank">PIII</a> <font color="#6f6f6f">Finviz</font>…
P3 Health Partners (PIII) Stock Surges Over 42% After Hours: Here's Why - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTzdzY2hsNzlVc0pyRzFNcldWQ1hYVl9hRkZ0X3VRNmdzQlJNdktXWjFzTUJTNWhxVm1CS2xWeURXSVNVUThvRkNHbzFkcTIwZmZtTFg4OF9iOERvN0NFZmhnUC0tTU9RNmFVeDFEYWpvaW1xNERLVnNzVXlBY05FZEpfUHNwNGRVRjhKRl…
P3 Health Partners Swung to Profit and Beat EPS by $5.17 — Is PIII Stock a Buy at $10? - TradingKey
<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxPZ2NTdEh5RkZFeTZTTzdKQko2d3pwM0ZtUVlKS1ozMk1vR0xPU01WTUtMRUVwbTNQdk1OTVdHcXc2NkUtMkt5Y0tDYmx4UFZBcDJObnd2TGZMOUxBeF9iQTE0UFF3a2doSGYxbHlGWWdqTGRZVmVES2p5a21mdEpWV0g3MTRiUUg0TEpnaz…
P3 Health reports $15.7M net income, lifts 2026 EBITDA outlook - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOb1ducHg1UmlmSDgzeWNLMUJCZWVtOUdBejEzZTF0QUZ3dG0tZXVOQmRHUU1NcGhJeTFpX3JJalc0TG9YZ04ybXhhVmpORTNkLXd2TzZnb0pXdFhMaDJ3YkJNa3BRY1preERqaXR6ano1bHFhRkRubVk4a3J2Z2JrR0Q2ei1XSVdVQTJwWE…
PIII — Frequently Asked Questions
What is the current share price of P3 Health Partners Inc. (PIII)?
As of 2026-09-19 21:16 PDT, P3 Health Partners Inc. (PIII) trades at $8.98 on NasdaqCM. Its 52-week range is $1.52 to $16.47.
What is the market capitalisation of PIII?
P3 Health Partners Inc. (PIII) has a market capitalisation of $35.13M on NasdaqCM.
What is the P/E ratio of PIII?
PIII trades at a trailing price-to-earnings (P/E) ratio of -0.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.33.
Is PIII a good stock to buy?
This page provides a data-driven analysis of P3 Health Partners Inc. (PIII), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.